Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Mod Pathol
    July 2024
  1. RAMMAL R, Goel K, Motanagh SA, Carter GJ, et al
    Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
    Mod Pathol. 2024;37:100517.
    >> Share

    June 2024
  2. FARSHID G, Armes J, Dessauvagie B, Gilhotra A, et al
    Development and Validation of a HER2-Low Focused IHC Scoring System with High Inter-Observer Concordance The Australian HER2-low Breast Cancer Concordance Study.
    Mod Pathol. 2024 Jun 7:100535. doi: 10.1016/j.modpat.2024.100535.
    >> Share

    May 2024
  3. INGEBRIKTSEN LM, Svanoe AA, Saele AKM, Humlevik ROC, et al
    Age-related clusters and favorable immune phenotypes in breast cancer of the young.
    Mod Pathol. 2024 May 27:100529. doi: 10.1016/j.modpat.2024.100529.
    >> Share

  4. AJABNOOR R, Zhang G, Hu Y, Gao Y, et al
    Breast Cancer with HER2 IHC 2+ and Average HER2 Signals/Cell >/= 6 and HER2/CEP17 Ratio < 2: A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.
    Mod Pathol. 2024 May 27:100530. doi: 10.1016/j.modpat.2024.100530.
    >> Share

  5. DJERROUDI L, El Sabeh-Ayoun A, Benoist C, Pierron G, et al
    Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.
    Mod Pathol. 2024;37:100463.
    >> Share

    April 2024
  6. DE SCHEPPER M, Koorman T, Richard F, Christgen M, et al
    Integration of pathological criteria and immunohistochemical evaluation for invasive lobular carcinoma diagnosis: recommendations from the European Lobular Breast Cancer Consortium.
    Mod Pathol. 2024 Apr 17:100497. doi: 10.1016/j.modpat.2024.100497.
    >> Share

  7. HARINATH L, Villatoro TM, Clark BZ, Fine JL, et al
    Upgrade Rates of Variant Lobular Carcinoma In Situ Compared to Classic Lobular Carcinoma In Situ Diagnosed in Core Needle Biopsies: A 10-Year Single Institution Retrospective Study.
    Mod Pathol. 2024;37:100462.
    >> Share

    February 2024
  8. AL ASSAAD M, Michaud O, Semaan A, Sigouros M, et al
    Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets.
    Mod Pathol. 2024 Feb 16:100452. doi: 10.1016/j.modpat.2024.100452.
    >> Share

  9. SHAFIQUE A, Gonzalez R, Pantanowitz L, Tan PH, et al
    A Preliminary Investigation into Search and Matching for Tumor Discrimination in World Health Organization Breast Taxonomy Using Deep Networks.
    Mod Pathol. 2024;37:100381.
    >> Share

  10. DERAKHSHAN F, Da Cruz Paula A, Selenica P, da Silva EM, et al
    Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
    Mod Pathol. 2024;37:100375.
    >> Share

    January 2024
  11. SIQUEIRA JM, Mitani Y, Hoff CO, Bonini F, et al
    Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance.
    Mod Pathol. 2024;37:100371.
    >> Share

    December 2023
  12. IBRAHIM A, Jahanifar M, Wahab N, Toss MS, et al
    Artificial Intelligence-Based Mitosis Scoring in Breast Cancer: Clinical Application.
    Mod Pathol. 2023 Dec 26:100416. doi: 10.1016/j.modpat.2023.100416.
    >> Share

  13. LI X, Lee JH, Gao Y, Zhang J, et al
    Correlation of HER2 Protein Level with mRNA Level Quantified by RNAscope in Breast Cancer.
    Mod Pathol. 2023 Dec 20:100408. doi: 10.1016/j.modpat.2023.100408.
    >> Share

  14. IBRAHIM A, Toss MS, Alsaleem M, Makhlouf S, et al
    Novel Two Gene Signature Associated with Breast Cancer Proliferation: Insights from Predictive Differential Gene Expression Analysis.
    Mod Pathol. 2023 Dec 15:100403. doi: 10.1016/j.modpat.2023.100403.
    >> Share

    November 2023
  15. BAEZ-NAVARRO X, van Bockstal MR, Andrinopoulou ER, van Deurzen CHM, et al
    Corrigendum to "HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort" [Modern Pathology 36(4) 100087].
    Mod Pathol. 2023;36:100356.
    >> Share

  16. LIN LH, Tran I, Yang Y, Shen G, et al
    DNA Methylation Identifies Epigenetic Subtypes of Triple-Negative Breast Cancers With Distinct Clinicopathologic and Molecular Features.
    Mod Pathol. 2023;36:100306.
    >> Share

  17. SHEN S, Ma W, Brown D, Da Cruz Paula A, et al
    HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.
    Mod Pathol. 2023;36:100299.
    >> Share

    August 2023
  18. RONG R, Sheng H, Jin KW, Wu F, et al
    A Deep Learning Approach for Histology-Based Nucleus Segmentation and Tumor Microenvironment Characterization.
    Mod Pathol. 2023;36:100196.
    >> Share

    July 2023
  19. MAKHLOUF S, Althobiti M, Toss M, Muftah AA, et al
    THE CLINICAL AND BIOLOGICAL SIGNIFICANCE OF ESTROGEN RECEPTOR-LOW POSITIVE BREAST CANCER.
    Mod Pathol. 2023 Jul 18:100284. doi: 10.1016/j.modpat.2023.100284.
    >> Share

  20. HU Y, Jones D, Zhao W, Tozbikian G, et al
    Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center.
    Mod Pathol. 2023;36:100164.
    >> Share

    June 2023
  21. ATALLAH NM, Wahab N, Toss MS, Makhlouf S, et al
    Deciphering the Morphology of Tumor-stromal Features in Invasive Breast Cancer Using Artificial Intelligence.
    Mod Pathol. 2023 Jun 26:100254. doi: 10.1016/j.modpat.2023.100254.
    >> Share

  22. BAKER GM, Bret-Mounet VC, Xu J, Fein-Zachary VJ, et al
    Toker Cell Hyperplasia in the Nipple-Areolar Complex of Transmasculine Individuals.
    Mod Pathol. 2023;36:100121.
    >> Share

    May 2023
  23. CHALLA B, Tahir M, Hu Y, Kellough D, et al
    Artificial Intelligence-Aided Diagnosis of Breast Cancer Lymph Node Metastasis on Histologic Slides in a Digital Workflow.
    Mod Pathol. 2023 May 11:100216. doi: 10.1016/j.modpat.2023.100216.
    >> Share

  24. CHRISTGEN M, Kreipe H
    Standardization in the Diagnosis of Invasive Lobular Carcinoma of the Breast.
    Mod Pathol. 2023;36:100163.
    >> Share

  25. SCHWARTZ CJ, Ruiz J, Bean GR, Sirohi D, et al
    Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
    Mod Pathol. 2023;36:100125.
    >> Share

    April 2023
  26. YEONG J, Goh D, Tan TJ, Tan B, et al
    Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression.
    Mod Pathol. 2023;36:100056.
    >> Share

    March 2023
  27. KRISHNAN A, Spegg V, Dettwiler S, Schraml P, et al
    Analysis of the PARP1, ADP-Ribosylation and TRIP12 Triad with Markers of Patient Outcome in Human Breast Cancer.
    Mod Pathol. 2023 Mar 27:100167. doi: 10.1016/j.modpat.2023.100167.
    >> Share

  28. ABELE N, Tiemann K, Krech T, Wellmann A, et al
    Noninferiority of Artificial Intelligence-Assisted Analysis of Ki-67 and Estrogen/Progesterone Receptor in Breast Cancer Routine Diagnostics.
    Mod Pathol. 2023;36:100033.
    >> Share

    February 2023
  29. KHOURY T, Rosa M, Nayak A, Karabakhtsian R, et al
    Clinicopathologic Predictors of Clinical Outcomes in Mammary Adenoid Cystic Carcinoma: A Multi-institutional Study.
    Mod Pathol. 2023;36:100006.
    >> Share

    January 2023
  30. MUELLER S, Grote I, Bartels S, Kandt L, et al
    p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.
    Mod Pathol. 2023;36:100100.
    >> Share

  31. WU S, Yue M, Zhang J, Li X, et al
    The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer.
    Mod Pathol. 2023;36:100054.
    >> Share

  32. BAEZ-NAVARRO X, van Bockstal MR, Andrinopoulou ER, van Deurzen CHM, et al
    HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort.
    Mod Pathol. 2023;36:100087.
    >> Share

  33. CALHOUN BC, Dabbs DJ
    Lack of Standardization in the Diagnosis of Invasive Lobular Carcinoma of the Breast.
    Mod Pathol. 2023;36:100041.
    >> Share

  34. ROBBINS CJ, Fernandez AI, Han G, Wong S, et al
    Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
    Mod Pathol. 2023;36:100032.
    >> Share

  35. BAEZ-NAVARRO X, van Bockstal MR, Nawawi D, Broeckx G, et al
    Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
    Mod Pathol. 2023;36:100009.
    >> Share

    November 2022
  36. CYRTA J, Benoist C, Masliah-Planchon J, Vieira AF, et al
    Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression.
    Mod Pathol. 2022;35:1624-1635.
    >> Share

  37. HARBHAJANKA A, Gilmore HL, Calhoun BC
    High-risk and selected benign breast lesions diagnosed on core needle biopsy: Evidence for and against immediate surgical excision.
    Mod Pathol. 2022;35:1500-1508.
    >> Share

    October 2022
  38. SIEGMUND SE, Manning DK, Davineni PK, Dong F, et al
    Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations.
    Mod Pathol. 2022;35:1458-1467.
    >> Share

  39. BEAN GR, Najjar S, Shin SJ, Hosfield EM, et al
    Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.
    Mod Pathol. 2022;35:1349-1361.
    >> Share

  40. VANDERBILT C, Brenn T, Moy AP, Harloe G, et al
    Association of HPV42 with digital papillary adenocarcinoma and the use of in situ hybridization for its distinction from acral hidradenoma and diagnosis at non-acral sites.
    Mod Pathol. 2022;35:1405-1410.
    >> Share

  41. SOONG TR, Dillon DA, Rice-Stitt TL, Wieczorek TJ, et al
    Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity.
    Mod Pathol. 2022;35:1370-1382.
    >> Share

    August 2022
  42. DE SCHEPPER M, Vincent-Salomon A, Christgen M, Van Baelen K, et al
    Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.
    Mod Pathol. 2022 Aug 3. pii: 10.1038/s41379-022-01135.
    >> Share

  43. ZHANG H, Katerji H, Turner BM, Audeh W, et al
    HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles.
    Mod Pathol. 2022;35:1075-1082.
    >> Share

  44. STRADELLA A, Gargallo P, Cejuela M, Petit A, et al
    Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.
    Mod Pathol. 2022;35:1066-1074.
    >> Share

    July 2022
  45. GROTE I, Bartels S, Christgen H, Radner M, et al
    ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
    Mod Pathol. 2022 Jul 16. pii: 10.1038/s41379-022-01130.
    >> Share

    June 2022
  46. ACS B, Leung SCY, Kidwell KM, Arun I, et al
    Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
    Mod Pathol. 2022 Jun 21. pii: 10.1038/s41379-022-01104.
    >> Share

  47. LUCHINI C, Pantanowitz L, Adsay V, Asa SL, et al
    Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring.
    Mod Pathol. 2022;35:712-720.
    >> Share

  48. BACHERT SE, Jen A, Denison C, Kwait D, et al
    Breast lesions associated with mammographic architectural distortion: a study of 588 core needle biopsies.
    Mod Pathol. 2022;35:728-738.
    >> Share

    May 2022
  49. LASHEN A, Toss MS, Alsaleem M, Green AR, et al
    The characteristics and clinical significance of atypical mitosis in breast cancer.
    Mod Pathol. 2022 May 2. pii: 10.1038/s41379-022-01080.
    >> Share

    April 2022
  50. WEI Y, Ke X, Yu J, Jing Q, et al
    Clinical and genomic analyses of neuroendocrine neoplasms of the breast.
    Mod Pathol. 2022;35:495-505.
    >> Share

  51. JEDRZKIEWICZ J, Sirohi D, Uvejzovic N, Gulbahce HE, et al
    RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory.
    Mod Pathol. 2022;35:549-553.
    >> Share

    March 2022
  52. KIM CF, Jou D, Ganor O, Boskey ER, et al
    Prostatic metaplasia and pilar differentiation in gender-affirming mastectomy specimens.
    Mod Pathol. 2022;35:386-395.
    >> Share

    January 2022
  53. SALAMA AM, Hanna MG, Giri D, Kezlarian B, et al
    Digital validation of breast biomarkers (ER, PR, AR, and HER2) in cytology specimens using three different scanners.
    Mod Pathol. 2022;35:52-59.
    >> Share

    December 2021
  54. IBRAHIM A, Lashen AG, Katayama A, Mihai R, et al
    Defining the area of mitoses counting in invasive breast cancer using whole slide image.
    Mod Pathol. 2021 Dec 11. pii: 10.1038/s41379-021-00981.
    >> Share

  55. VAN BOCKSTAL MR, Francois A, Altinay S, Arnould L, et al
    Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.
    Mod Pathol. 2021;34:2130-2140.
    >> Share

    November 2021
  56. SUN X, Zhai J, Sun B, Parra ER, et al
    Effector memory cytotoxic CD3(+)/CD8(+)/CD45RO(+) T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.
    Mod Pathol. 2021 Nov 27. pii: 10.1038/s41379-021-00973.
    >> Share

    October 2021
  57. CLOUTIER JM, Kunder CA, Charville GW, Hosfield EM, et al
    Nodular fasciitis of the breast: clinicopathologic and molecular characterization with identification of novel USP6 fusion partners.
    Mod Pathol. 2021;34:1865-1875.
    >> Share

  58. SCHWARTZ CJ, Pareja F, da Silva EM, Selenica P, et al
    Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes.
    Mod Pathol. 2021;34:1850-1859.
    >> Share

    September 2021
  59. FERGUSON DC, Mata DA, Tay TK, Traina TA, et al
    Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations.
    Mod Pathol. 2021 Sep 30. pii: 10.1038/s41379-021-00924.
    >> Share

    August 2021
  60. D'ALFONSO TM, Ho DJ, Hanna MG, Grabenstetter A, et al
    Multi-magnification-based machine learning as an ancillary tool for the pathologic assessment of shaved margins for breast carcinoma lumpectomy specimens.
    Mod Pathol. 2021;34:1487-1494.
    >> Share

  61. KUBA MG, Murray MP, Coffey K, Calle C, et al
    Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision.
    Mod Pathol. 2021;34:1495-1506.
    >> Share

    July 2021
  62. BERGERON A, MacGrogan G, Bertaut A, Ladoire S, et al
    Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.
    Mod Pathol. 2021;34:1282-1296.
    >> Share

  63. NG CCY, Md Nasir ND, Loke BN, Tay TKY, et al
    Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.
    Mod Pathol. 2021;34:1320-1332.
    >> Share

  64. GRABENSTETTER A, Alfonso TM, Wen HY, Murray M, et al
    Morphologic and immunohistochemical features of carcinoma involving microglandular adenosis of the breast following neoadjuvant chemotherapy.
    Mod Pathol. 2021;34:1310-1319.
    >> Share

  65. AUNG TN, Acs B, Warrell J, Bai Y, et al
    A new tool for technical standardization of the Ki67 immunohistochemical assay.
    Mod Pathol. 2021;34:1261-1270.
    >> Share

    June 2021
  66. TAY TKY, Tan PH
    Papillary neoplasms of the breast-reviewing the spectrum.
    Mod Pathol. 2021;34:1044-1061.
    >> Share

    April 2021
  67. GINTER PS, Idress R, D'Alfonso TM, Fineberg S, et al
    Histologic grading of breast carcinoma: a multi-institution study of interobserver variation using virtual microscopy.
    Mod Pathol. 2021;34:701-709.
    >> Share

    March 2021
  68. KUBA MG, Lester SC, Bowman T, Stokes SM, et al
    Histopathologic features of breast cancer in Li-Fraumeni syndrome.
    Mod Pathol. 2021;34:542-548.
    >> Share

    February 2021
  69. ALDREES R, Gao X, Zhang K, Siegal GP, et al
    Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution.
    Mod Pathol. 2021;34:291-299.
    >> Share

    January 2021
  70. ALLISON KH
    Prognostic and predictive parameters in breast pathology: a pathologist's primer.
    Mod Pathol. 2021;34.
    >> Share

  71. CIMINO-MATHEWS A
    Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.
    Mod Pathol. 2021;34.
    >> Share

  72. BROGI E, Krystel-Whittemore M
    Papillary neoplasms of the breast including upgrade rates and management of intraductal papilloma without atypia diagnosed at core needle biopsy.
    Mod Pathol. 2021;34.
    >> Share

  73. PAREJA F, Weigelt B, Reis-Filho JS
    Problematic breast tumors reassessed in light of novel molecular data.
    Mod Pathol. 2021;34.
    >> Share

  74. SOKOLOVA A, Lakhani SR
    Lobular carcinoma in situ: diagnostic criteria and molecular correlates.
    Mod Pathol. 2021;34.
    >> Share

  75. SCHNITT SJ
    Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy.
    Mod Pathol. 2021;34.
    >> Share

  76. COLLINS LC
    Precision pathology as applied to breast core needle biopsy evaluation: implications for management.
    Mod Pathol. 2021;34.
    >> Share

  77. TAN PH
    Fibroepithelial lesions revisited: implications for diagnosis and management.
    Mod Pathol. 2021;34.
    >> Share

  78. BASKOTA SU, Dabbs DJ, Clark BZ, Bhargava R, et al
    Prosigna(R) breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK) index for breast cancer prognosis.
    Mod Pathol. 2021;34:70-76.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016